Mirum Pharmaceuticals Appoints Biotechnology Executive William C. Fairey to its Board of Directors
August 19 2021 - 5:30PM
Business Wire
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the
appointment of industry veteran William C. Fairey to its Board of
Directors. Mr. Fairey brings to Mirum significant experience in
establishing commercial organizations within public companies,
building markets, and launching novel therapeutics to treat
specialty and rare and orphan diseases.
Concurrent with the appointment of Mr. Fairey, Tiba Aynechi,
Ph.D., has resigned from the Company’s Board of Directors and her
position on the Board’s Compensation and Nominating and Corporate
Governance Committees, respectively, effective August 19, 2021. Dr.
Aynechi has been a valued Director since Mirum’s inception in
2018.
“Bill’s extensive experience in global commercial and corporate
strategy, and in rare disease, will be instrumental as we prepare
for the launch of our first medication in the U.S. and continue to
advance our pipeline to deliver medications for patients with rare
liver diseases globally,” said Chris Peetz, President and Chief
Executive Officer at Mirum. “On behalf of the Board of Directors, I
want to thank Tiba for her leadership and significant contributions
as a founding Board member of Mirum. Her confidence in Mirum and
sagacious guidance in the early days of the company helped Mirum to
move from clinical-stage to a commercial-ready company, poised to
make a meaningful impact for the rare liver disease community.”
Mr. Fairey brings nearly 30 years of experience building strong
and scalable global commercial organizations. Most recently, Mr.
Fairey served as Executive Vice President and Chief Commercial
Officer at MyoKardia, where he built the commercial and portfolio
strategy, established the company’s European headquarters, was
planning for the expansion in Latin America and Asia when the
company was acquired by Bristol-Myers Squibb. Mr. Fairey held a
similar role at ChemoCentryx, where, as Chief Operating Officer, he
was responsible for building out the initial commercial and medical
teams. Prior to ChemoCentryx, he served in a number of roles at
Actelion Pharmaceuticals, including President of the U.S. division.
Before taking that role, Mr. Fairey developed Actelion’s
Asia-Pacific business, creating new opportunities in China, Taiwan,
and Southeast Asia, and chaired the Board of Directors for Actelion
China. He was also President of Actelion Canada and as Vice
President, Sales and Managed Markets, one of the founding members
of the U.S. executive team.
“I am excited to join Mirum’s Board to champion and help to grow
what is already a strong and capable organization with a proven
commitment to developing life-changing medicines,” said William C.
Fairey. “I look forward to supporting Mirum’s efforts as they
prepare for the potential launch of their first medication in the
U.S., and as they expand their reach to the rare disease
communities globally.”
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a late-stage pipeline of novel therapies for
debilitating liver diseases. Mirum’s lead product candidate,
maralixibat, is an investigational oral drug in development for
Alagille syndrome (ALGS), progressive familial intrahepatic
cholestasis (PFIC), and biliary atresia. Mirum has submitted an NDA
for maralixibat in the treatment of cholestatic pruritus in
patients with ALGS. The NDA has been accepted for priority review
by the FDA with a PDUFA action date of September 29, 2021.
Additionally, Mirum’s marketing authorization application for the
treatment of pediatric patients with PFIC2 has been accepted for
review (validated) by the European Medicines Agency. Mirum is also
developing volixibat, also an oral ASBT-inhibitor, in primary
sclerosing cholangitis, intrahepatic cholestasis of pregnancy, and
primary biliary cholangitis. For more information, visit
MirumPharma.com.
To augment its pipeline in cholestatic liver disease, Mirum has
acquired the exclusive option to develop and commercialize gene
therapy programs VTX-803 and VTX-802 for PFIC3 and PFIC2,
respectively, from Vivet Therapeutics SAS, following preclinical
evaluation and investigational new drug-enabling studies.
Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements include statements
regarding, among other things, the regulatory approval pathway for
maralixibat. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Words such
as “will,” “could,” “would,” “potential” and similar expressions
are intended to identify forward-looking statements. These
forward-looking statements are based upon Mirum’s current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results could differ materially
from those anticipated in such forward-looking statements as a
result of various risks and uncertainties, which include, without
limitation, risks and uncertainties associated with Mirum’s
business in general, the impact of the COVID-19 pandemic, and the
other risks described in Mirum’s filings with the Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. Mirum undertakes no obligation to update such statements
to reflect events that occur or circumstances that exist after the
date on which they were made, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210819005783/en/
Media: Erin Murphy media@mirumpharma.com
Investors: Ian Clements, Ph.D. ir@mirumpharma.com
Sam Martin Argot Partners ir@mirumpharma.com
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Apr 2023 to Apr 2024